| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2131238 | Experimental Cell Research | 2011 | 8 Pages |
Abstract
Several novel technologies have evolved over the last decade for the modification of antibodies to enhance their inherent effector functions. All focus on the constant Fc domain and utilize either amino acid substitutions or glycoform perturbations to modulate their interaction with Fc receptors and the effector cells that bear them. We review these technologies with an emphasis on their validation with animal models and human clinical data.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
John R. Desjarlais, Greg A. Lazar,
